Aua Capital Management LLC Increases Position in AbbVie Inc. (NYSE:ABBV)

Aua Capital Management LLC boosted its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 3.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,813 shares of the company’s stock after acquiring an additional 104 shares during the period. Aua Capital Management LLC’s holdings in AbbVie were worth $512,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the company. Vermillion & White Wealth Management Group LLC acquired a new position in shares of AbbVie in the 4th quarter worth approximately $26,000. Able Wealth Management LLC acquired a new stake in AbbVie during the 4th quarter worth approximately $33,000. IFS Advisors LLC acquired a new stake in AbbVie during the 1st quarter worth approximately $36,000. Ables Iannone Moore & Associates Inc. acquired a new stake in AbbVie during the 4th quarter worth approximately $37,000. Finally, Clarity Asset Management Inc. acquired a new stake in AbbVie during the 4th quarter worth approximately $42,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Trading Down 1.0 %

Shares of AbbVie stock opened at $170.39 on Monday. AbbVie Inc. has a 1 year low of $130.96 and a 1 year high of $182.89. The company has a debt-to-equity ratio of 7.93, a quick ratio of 0.83 and a current ratio of 0.94. The company has a market capitalization of $300.89 billion, a P/E ratio of 50.56, a PEG ratio of 2.20 and a beta of 0.60. The company’s fifty day moving average is $163.89 and its two-hundred day moving average is $166.93.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, May 3rd. The company reported $2.31 EPS for the quarter, topping the consensus estimate of $2.26 by $0.05. AbbVie had a net margin of 11.02% and a return on equity of 179.47%. The company had revenue of $12.31 billion during the quarter, compared to analysts’ expectations of $11.93 billion. During the same quarter last year, the business earned $2.46 EPS. The business’s revenue was up .7% on a year-over-year basis. Analysts forecast that AbbVie Inc. will post 11.27 earnings per share for the current year.

AbbVie Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, August 15th. Stockholders of record on Monday, July 15th will be paid a $1.55 dividend. This represents a $6.20 annualized dividend and a dividend yield of 3.64%. The ex-dividend date of this dividend is Monday, July 15th. AbbVie’s dividend payout ratio (DPR) is presently 183.98%.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Barclays reduced their target price on shares of AbbVie from $195.00 to $187.00 and set an “overweight” rating on the stock in a report on Monday, April 29th. BMO Capital Markets dropped their price objective on shares of AbbVie from $195.00 to $180.00 and set an “outperform” rating on the stock in a research report on Monday, April 29th. Piper Sandler increased their price objective on shares of AbbVie from $185.00 to $190.00 and gave the company an “overweight” rating in a research report on Tuesday, June 18th. Cantor Fitzgerald reissued an “overweight” rating and issued a $200.00 price objective on shares of AbbVie in a research report on Thursday. Finally, Guggenheim increased their price objective on shares of AbbVie from $188.00 to $190.00 and gave the company a “buy” rating in a research report on Friday, March 22nd. Two analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $179.64.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.